Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization

Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization

Paolo Milani, Amedeo Massacesi, Stefano Ciaccia, Marco Setaccioli, Stefania Moschini, Fulvio BergaminiDipartimento di Oculistica, Istituto Auxologico Italiano, Milano, ItalyBackground: The aim of this study was to evaluate the efficacy of intravitreal bevacizumab when administered on an as-needed ba...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bergamini F, Moschini S, Setaccioli M, Ciaccia S, Massacesi A, Milani P
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/8853ba05e850495e89b7caf57fc51a6f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8853ba05e850495e89b7caf57fc51a6f
record_format dspace
spelling oai:doaj.org-article:8853ba05e850495e89b7caf57fc51a6f2021-12-02T07:07:37ZOnly first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization1177-54671177-5483https://doaj.org/article/8853ba05e850495e89b7caf57fc51a6f2012-11-01T00:00:00Zhttp://www.dovepress.com/only-first-intravitreal-bevacizumab-injection-achieves-statistically-s-a11544https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Paolo Milani, Amedeo Massacesi, Stefano Ciaccia, Marco Setaccioli, Stefania Moschini, Fulvio BergaminiDipartimento di Oculistica, Istituto Auxologico Italiano, Milano, ItalyBackground: The aim of this study was to evaluate the efficacy of intravitreal bevacizumab when administered on an as-needed basis for the treatment of myopic choroidal neovascularization (CNV), and to assess visual changes upon treatment.Methods: This study was designed as a retrospective, interventional case series, for which the inclusion criteria were pathologic myopia, and documentation of untreated active macular CNV on fluorescein angiography and optical coherence tomography. Monthly changes in best-corrected visual acuity (BCVA), visual gain after each treatment, and correlation with refraction, age, location, and dimension of CNV were considered. The data were analyzed using the one-tailed, paired Wilcoxon test.Results: Nineteen naive eyes were found suitable for the study. The mean number of treatments was 3.32 ± 2.36 (confidence interval 2.25–4.37) during a mean follow-up period of 18.95 ± 8.3 months. At baseline, mean BCVA was 0.58 ± 0.37 logarithm of the minimum angle of resolution (logMAR) units. At 12 months, mean BCVA was 0.39 ± 0.35 logMAR and at 24 months was 0.39 ± 0.40. Mean improvement in BCVA from baseline was +0.17 ± 0.25 logMAR (P < 0.05) at month 12, +0.14 ± 0.25 logMAR (P = 0.1) at month 18, and +0.09 ± 0.32 logMAR (P = 0.5) at month 24. Improvement on pretreatment BCVA was significant (+0.16 logMAR, P < 0.01) after the first injection, but not after the second (−0.01 logMAR, P = 0.5) or third (+0.02 logMAR, P = 0.5) injections. There was a statistically significant correlation between age and number of treatments, and between improvement in BCVA of foveal versus extrafoveal location of CNV.Conclusion: The use of intravitreal bevacizumab "as needed" is an effective treatment for myopic CNV, but visual gain is statistically significant only after the first injection and decreases in the second year.Keywords: choroidal neovascularization, macular degeneration, pathologic myopia, bevacizumab, optical coherence tomographyBergamini FMoschini SSetaccioli MCiaccia SMassacesi AMilani PDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1885-1894 (2012)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Bergamini F
Moschini S
Setaccioli M
Ciaccia S
Massacesi A
Milani P
Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
description Paolo Milani, Amedeo Massacesi, Stefano Ciaccia, Marco Setaccioli, Stefania Moschini, Fulvio BergaminiDipartimento di Oculistica, Istituto Auxologico Italiano, Milano, ItalyBackground: The aim of this study was to evaluate the efficacy of intravitreal bevacizumab when administered on an as-needed basis for the treatment of myopic choroidal neovascularization (CNV), and to assess visual changes upon treatment.Methods: This study was designed as a retrospective, interventional case series, for which the inclusion criteria were pathologic myopia, and documentation of untreated active macular CNV on fluorescein angiography and optical coherence tomography. Monthly changes in best-corrected visual acuity (BCVA), visual gain after each treatment, and correlation with refraction, age, location, and dimension of CNV were considered. The data were analyzed using the one-tailed, paired Wilcoxon test.Results: Nineteen naive eyes were found suitable for the study. The mean number of treatments was 3.32 ± 2.36 (confidence interval 2.25–4.37) during a mean follow-up period of 18.95 ± 8.3 months. At baseline, mean BCVA was 0.58 ± 0.37 logarithm of the minimum angle of resolution (logMAR) units. At 12 months, mean BCVA was 0.39 ± 0.35 logMAR and at 24 months was 0.39 ± 0.40. Mean improvement in BCVA from baseline was +0.17 ± 0.25 logMAR (P < 0.05) at month 12, +0.14 ± 0.25 logMAR (P = 0.1) at month 18, and +0.09 ± 0.32 logMAR (P = 0.5) at month 24. Improvement on pretreatment BCVA was significant (+0.16 logMAR, P < 0.01) after the first injection, but not after the second (−0.01 logMAR, P = 0.5) or third (+0.02 logMAR, P = 0.5) injections. There was a statistically significant correlation between age and number of treatments, and between improvement in BCVA of foveal versus extrafoveal location of CNV.Conclusion: The use of intravitreal bevacizumab "as needed" is an effective treatment for myopic CNV, but visual gain is statistically significant only after the first injection and decreases in the second year.Keywords: choroidal neovascularization, macular degeneration, pathologic myopia, bevacizumab, optical coherence tomography
format article
author Bergamini F
Moschini S
Setaccioli M
Ciaccia S
Massacesi A
Milani P
author_facet Bergamini F
Moschini S
Setaccioli M
Ciaccia S
Massacesi A
Milani P
author_sort Bergamini F
title Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
title_short Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
title_full Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
title_fullStr Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
title_full_unstemmed Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
title_sort only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/8853ba05e850495e89b7caf57fc51a6f
work_keys_str_mv AT bergaminif onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
AT moschinis onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
AT setacciolim onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
AT ciaccias onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
AT massacesia onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
AT milanip onlyfirstintravitrealbevacizumabinjectionachievesstatisticallysignificantvisualimprovementinnaampiumlvemyopicchoroidalneovascularization
_version_ 1718399584020987904

Ejemplares similares